(Q73367762)

English

Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: A case report

scientific article published on 01 January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: A case report (English)

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

author name string

Masato Takahashi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Ken-ichi Inoue

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Ryoichi Goto

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Motoshi Tamura

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Kazunori Taguchi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Hiromasa Takahashi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Hiroaki Suzuki

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Katsushige Katsushige

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Masami Ogita

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12736573

31 December 2023

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF02967645.pdf

Portable Document Format

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

http://link.springer.com/article/10.1007/BF02967645/fulltext.html

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

http://link.springer.com/content/pdf/10.1007/BF02967645

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

170-174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12736573%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

describes a project that uses

fluorescence in situ hybridization

1 reference

based on heuristic

inferred from title

https://scigraph.springernature.com/pub.10.1007/bf02967645

0 references

Effectiveness of mass screening for breast cancer in Japan

1

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

2

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Treatment of breast cancer

3

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer

4

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer

6

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Evaluating HER2 amplification and overexpression in breast cancer.

7

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

9

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Improving the efficacy of antibody-based cancer therapies

10

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

11

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

12

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

16

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Herceptin (trastuzamab) in advanced breast cancer

17

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

18

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

19

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

20

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

21

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

22

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

24

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

25

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan

26

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

27

1 reference

10.1007/BF02967645

https://api.crossref.org/works/10.1007/BF02967645

31 December 2023

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73367762&oldid=2041468461"